Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis
- 7 June 2014
- journal article
- Published by Informa Healthcare in Expert Opinion on Drug Delivery
- Vol. 11 (10) , 1551-1560
Abstract
Test the hypothesis that pegylated meglumine antimoniate-containing liposomes (LMA) and their mixture with non-pegylated (conventional) LMA may be more effective than conventional LMA against visceral leishmaniasis (VL), because of wider drug distribution among different mononuclear phagocyte system (MPS) tissues. Sb was determined in the blood and MPS tissues after administration of pegylated or conventional LMA intravenously to mongrel dogs naturally infected with Leishmania infantum and Swiss mice. Pegylated and conventional LMA as well as their mixture were evaluated for their antileishmanial efficacy in BALB/c infected with L. infantum through determination of parasite load in liver, spleen and bone marrow. An improved targeting of Sb to the bone marrow of dogs was clearly evidenced, as an important impact of pegylation. In accordance with this data, pegylated LMA significantly reduced parasite load in bone marrow of infected mice, in contrast to conventional LMA. The mixed formulation of conventional and pegylated LMA promoted parasite suppression to a higher extent in both spleen and bone marrow, compared to pegylated or conventional LMA. The present work establishes for the first time the potential of mixed formulations of conventional and pegylated liposomes as a drug delivery strategy for improved treatment of VL.Keywords
This publication has 21 references indexed in Scilit:
- Leishmaniasis Worldwide and Global Estimates of Its IncidencePLOS ONE, 2012
- New delivery strategies for the old pentavalent antimonial drugsExpert Opinion on Drug Delivery, 2010
- Pentavalent Antimonials: New Perspectives for Old DrugsMolecules, 2009
- Improved targeting of antimony to the bone marrow of dogs using liposomes of reduced sizeInternational Journal of Pharmaceutics, 2006
- Canine Leishmaniasis2004
- Novel methods for the encapsulation of meglumine antimoniate into liposomesBrazilian Journal of Medical and Biological Research, 2000
- U.S. Food and Drug Administration Approval of AmBisome (Liposomal Amphotericin B) for Treatment of Visceral LeishmaniasisClinical Infectious Diseases, 1999
- Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantumJournal of Antimicrobial Chemotherapy, 1995
- Liposomes as drug carriers in leishmaniasis and malariaParasitology Today, 1986
- The use of Pentostam liposomes in the chemotherapy of experimental leishmaniasisTransactions of the Royal Society of Tropical Medicine and Hygiene, 1977